Clinical Trials Directory

Trials / Completed

CompletedNCT01801293

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
8 (actual)
Sponsor
Gilead Sciences · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This is a single center, open-label, Phase 1 study to determine the mass balance of of GS-5806 following administration of a single, oral dose of radiolabeled \[14C\]-GS-5806 in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGGS-5806

Timeline

Start date
2013-03-01
Primary completion
2013-04-01
Completion
2013-04-01
First posted
2013-02-28
Last updated
2013-06-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01801293. Inclusion in this directory is not an endorsement.

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 (NCT01801293) · Clinical Trials Directory